Latest News for: alz

Edit

Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early ...

Business Wire 10 Apr 2025
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical ...
Edit

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

PR Newswire 02 Apr 2025
Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology ... This underscores the dual-action profile of HT-ALZ—impacting both pathology and symptomology.
Edit

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

PR Newswire 02 Apr 2025
The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD).
Edit

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

The Eagle-Tribune 25 Mar 2025
Simufilam did not show a significant reduction in co-primary ...
Edit

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (Form 8-K) (Cassava Sciences Inc)

Public Technologies 25 Mar 2025
REFOCUS-ALZ enrolled ... "We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease ... About REFOCUS-ALZ.
  • 1
×